<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340430</url>
  </required_header>
  <id_info>
    <org_study_id>NEOHER-021</org_study_id>
    <secondary_id>2010-021600-24</secondary_id>
    <nct_id>NCT01340430</nct_id>
  </id_info>
  <brief_title>Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer</brief_title>
  <official_title>Neoadjuvant Therapy With FEC Followed by Weekly Paclitaxel and Concurrent Trastuzumab in Her2 Positive Non Operable Breast Cancer. Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lucia Del Mastro,MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to confirm the high pathologic complete response rate after
      neoadjuvant chemotherapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in
      Human Epidermal growth factor receptor2 (HER2) positive non operable breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response</measure>
    <time_frame>at definitive surgery within 4 weeks after the last dose of paclitaxel and concurrent trastuzumab</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>one year</time_frame>
    <description>safety and tolerability will be assessed by standard clinical and laboratory tests (hematology, serum chemistry). Toxicity grade is defined by the NCI Common Toxicity Criteria (CTC) Adverse Event (AE) v 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiotoxicity</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of conversion from radical to conservative surgery</measure>
    <time_frame>definitive surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>potential biomarkers of trastuzumab resistance</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>HER-2 Positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>FEC-paclitaxel-trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluorouracil 600 mg/m2; epirubicin 90 mg/m2; cyclophosphamide 600 mg/m2 for 4 cycles followed by paclitaxel 80 mg/m2/week in combination with trastuzumab for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab</description>
    <arm_group_label>FEC-paclitaxel-trastuzumab</arm_group_label>
    <other_name>herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Performance StatusEstearn Cooperative Oncology Group (ECOG) 0-1

          2. Histologically confirmed invasive breast cancer,

          3. Primary tumour greater ≥ 2 cm diameter, measured by clinical examination and
             mammography or echography or Nuclear Magnetic Resonance (NMR) candidate to neoadjuvant
             chemotherapy ,

          4. Any N,

          5. No evidence of metastasis (M0);

          6. Over expression and/or amplification of HER2 in the invasive component of the primary
             tumour according to one of the following definitions:

          7. 3+ over expression by immunohistochemistry (IHC) (&gt; 30% of invasive tumour cells),

          8. 2+ or 3+ (in 30% o less neoplastic cells) overexpression by IHC and in situ
             hybridization (FISH/CISH) test demonstrating Her2 gene amplication ,

          9. Her 2 gene amplication by FISH/CISH (ratio &gt; 2.2);

         10. Known hormone receptor status

         11. Hematopoietic status:

               1. absolute neutrophil count ≥ 1.5 x 109/L,

               2. platelet count ≥ 100 x 109/L,

         12. Hepatic status:

               1. serum total bilirubin ≤ 1.5 x ULN. In the case of known Gilbert's syndrome a
                  higher serum total bilirubin (&lt; 2 x ULN) is allowed,

               2. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times
                  ULN,

               3. alkaline phosphatase ≤ 2.5 times ULN;

         13. Renal status:

             a. Creatinine ≤ 2.0 mg/dL;

         14. Cardiovascular:

             a. baseline left ventricular ejection fraction (LVEF) ≥ 50% measured by
             echocardiography or multigate acquisition scan (MUGA);

         15. For women of childbearing potential negative serum pregnancy test

         16. Written informed consent.

        Exclusion Criteria:

          1. Male gender

          2. Pregnant or lactating women

          3. Received any prior treatment for primary invasive breast cancer

          4. Known history of uncontrolled or symptomatic angina, clinically significant
             arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled
             hypertension (&gt; 180/110), unstable diabetes mellitus, dyspnoea at rest or chronic
             therapy with oxygen;

          5. Active or uncontrolled infection,

          6. Dementia altered mental status or any psychiatric condition that would prevent the
             under standing or rendering of informed consent,

          7. Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy,
             biologic therapy other than the trial therapies),

          8. Previous or concomitant malignancy within the past 3 years EXCEPT adequately treated
             basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix.

          9. Concurrent disease or condition that would have make the subject inappropriate for
             study participation or any serious medical disorder that would interfere with the
             subject's safety.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucia Del Mastro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute For Cancer Reasearch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Nazionale per La Ricerca sul Cancro (IST)</name>
      <address>
        <city>Genoa</city>
        <state>Ge</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria della Misericordia - Oncologia Medica</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia - IRCC di Candiolo</name>
      <address>
        <city>Candiolo</city>
        <state>TO</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ostetrico Ginecologico S. Anna Di Torino - Oncologia Medica</name>
      <address>
        <city>Torino</city>
        <state>To</state>
        <zip>10100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mauriziano Umberto I - Ginecologia Oncologica</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore - Don Calabria - Oncologia Medica</name>
      <address>
        <city>Negrar</city>
        <state>VR</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2011</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</investigator_affiliation>
    <investigator_full_name>Lucia Del Mastro,MD</investigator_full_name>
    <investigator_title>md</investigator_title>
  </responsible_party>
  <keyword>her2 positive breast cancer</keyword>
  <keyword>her2 positive non operable breast cancer</keyword>
  <keyword>her2 positive locally advanced breast cancer</keyword>
  <keyword>neoadjuvant trastuzumab</keyword>
  <keyword>pathologic complete response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

